Crossmark

Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system

Crossref DOI link: https://doi.org/10.1007/s10198-020-01207-7

Published Online: 2020-06-06

Published Print: 2020-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Tsung-Ying https://orcid.org/0000-0003-0633-3140
Chen, Hsuan-Ying

Chen, Tsai-Yun

Li, Sin-Syue

Fang, Wei-Tse

Wen, Yao-Chun

Lo, Yu-Wen

Ou, Huang-Tz
Funding

Funding for this research was provided by:

Pfizer, Inc.

Ministry of Science and Technology, Taiwan (MOST 107-2320-B-006-034)
License Information

Text and Data Mining valid from 2020-06-06

Version of Record valid from 2020-06-06
More Information

Article History

Received: 29 November 2019

Accepted: 29 May 2020

First Online: 6 June 2020

Compliance with ethical standards

:

: TYL, HYC, TYC, SSL and HTO have no conflicts of interest. YCW, WTF and YWL are employees of Pfizer.

: This study was approved by the Institutional Review Board of National Cheng Kung University Hospital (A-EX-106-029).

Document is current

Any future updates will be listed below